Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S (NYSE:NVO ...

the Danish pharmaceutical behemoth Novo Nordisk A/S (NYSE:NVO) abruptly announced the resignation of veteran CEO Lars Fruergaard Jørgensenm last week. The stock has dropped by over 49% in the ...

In another note of news, a key aide to HHS Secretary Robert F. Kennedy Jr. said that popular GLP-1 weight loss drugs -- Novo Nordisk's ( NVO) Wegovy (semaglutide) and Eli Lilly's ( LLY) Zepbound ...

Discover the latest executive changes across major companies like UnitedHealth, Intuitive, Novo Nordisk, and more.

What happened to 23andMe? Here's a look at its history from launch to bankruptcy and acquisition by Regeneron.

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...